Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Anemia, Sickle Cell
Interventions
DRUG

Nitric Oxide

Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.

DRUG

Placebo

Nitrogen gas will be delivered in the same manor as the experimental drug.

Trial Locations (11)

19134

St. Christopher's Hospital for Children, Philadelphia

20060

Howard University Hospital, Washington D.C.

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

21205

Johns Hopkins University, Baltimore

35294

University of Alabama, Birmingham

80045

Colorado Sickle Cell Treatement and Research Center, Aurora

94609-1809

Children's Hospital Oakland, Oakland

02115

Brigham and Women's Hospital, Boston

Childrens Hospital, Boston, Boston

44106-2602

Case Western Reserve University Hospital, Cleveland

15213-2583

Childrens Hospital, Pittsburgh, Pittsburgh

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Mallinckrodt

INDUSTRY

NCT00094887 - Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises | Biotech Hunter | Biotech Hunter